debt_leverage_profile
Net cash position; no significant debt. ~$300M+ cash runway as of 2023. 20% rate rise has negligible P&L impact.
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal sensitivity; Immatics holds cash/equivalents with no material floating-rate debt. Rate rises slightly boost interest income.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) U.S.-Germany biotech reagent/GMP manufacturing corridor; 2) Taiwan/Asia semiconductor supply for lab instrumentation.
Inferred
Agent_Inference
international_expansion_readiness
Revenue primarily USD-denominated via U.S. partnerships (BMS, Genmab). EUR/USD devaluation risk modest; no major EM currency exposure.
Inferred
Agent_Inference
geographic_footprint
Operations in U.S. (Houston) and Germany (Tübingen). Revenues USD-dominated; EUR operational costs create mild FX translation risk.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
CROs and GMP manufacturers are critical single-source for clinical-stage TCR/CAR-T manufacturing; substitution risk is high and costly.
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption risk is low-moderate; proprietary XPRESIDENT/XCEPTOR platforms could face data migration delays but are not cloud-native SaaS.
Inferred
Agent_Inference
business_model_type_secondary
Biopharmaceutical R&D/partnership licensing model; cloud termination would disrupt bioinformatics pipelines but not core wet-lab operations.
Inferred
Agent_Inference
switching_cost_profile
Moderate API/platform coupling risk in bioinformatics tools; proprietary target discovery platform creates internal lock-in, not vendor API dependency.
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is milestone/royalty licensing from pharma partners—not a securities offering. Howey Test risk is very low/not applicable.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Patient genomic/clinical trial data processed across U.S. and Germany; subject to GDPR (DE) and U.S. HIPAA. Compliance costs material but manageable.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; early-stage oncology biotech in fragmented market with no dominant market share or exclusionary conduct concerns.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% non-recurring transactional/milestone-based collaboration revenue; no subscription model. Revenue highly lumpy and milestone-dependent.
Inferred
Agent_Inference
monetization_vector
Upfront licensing fees, R&D reimbursements, and milestone/royalty payments from pharma partners (BMS, Genmab, AstraZeneca).
Inferred
Agent_Inference
pricing_architecture
Pricing set via bilateral pharma negotiation; milestone values fixed in contracts. Limited real-time pricing flexibility; royalty rates typically 5–15%.
Inferred
Agent_Inference
pricing_power_rating
Moderate; proprietary TCR target discovery (XPRESIDENT) provides differentiation, but competition from Adaptimmune, TCR2 limits ceiling pricing.
Inferred
Agent_Inference
target_gross_margin_bracket
Collaboration revenue gross margin potentially 60–80%; R&D reimbursement revenues near breakeven. Overall blended margin negative due to burn.
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; IP-protected platform with contractual partnership structures. Partner attrition risk exists if clinical trials fail.
Inferred
Agent_Inference
headcount_cost_structure
Headcount-linear at current stage; scaling clinical programs requires proportional scientific/clinical staff growth. Not yet at sublinear scale.
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost of growth; each new clinical program requires significant incremental R&D, manufacturing, and regulatory headcount investment.
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC would compress as platform reputation grows; but clinical trial costs per program remain fixed—economics improve via royalties.
Inferred
Agent_Inference
network_effect_present
No traditional network effects; value accrues from proprietary data/IP accumulation (XPRESIDENT target library), creating a data moat, not network effect.
Inferred
Agent_Inference
asset_efficiency_ratio
AI/ML tools enhance target discovery efficiency; AI displacement of wet-lab biology is limited near-term. Platform bioinformatics partially AI-augmented.
Inferred
Agent_Inference
recession_resistance_tier
Moderate resilience; oncology funding is relatively recession-resistant, but pharma partner R&D budget cuts could delay milestones.
Inferred
Agent_Inference
customer_segment_primary
Large-cap pharma/biotech partners (Bristol-Myers Squibb, Genmab, AstraZeneca) representing majority of collaboration revenue.
Inferred
Agent_Inference
customer_segment_secondary
U.S. government/NIH grants and academic collaborators as secondary, smaller revenue contributors.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated toward clinical-stage manufacturing and platform expansion (future-state); minimal legacy infrastructure reallocation needed.
Inferred
Agent_Inference
sec_cik
0001809196
High
SEC-EDGAR
ticker
IMTX
High
SEC-EDGAR